Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Tailored group exercise (Falls Management Exercise — FaME) reduces falls in community-dwelling older frequent fallers (an RCT)

Tailored group exercise (Falls Management Exercise — FaME) reduces falls in community-dwelling... Research letters 5. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in bone metabolism in rats with adjuvant arthritis. Inflammation cancer patients. Cancer Treat Rev 1996; 22: 265–87. 2004; 28: 15–21. 6. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. 24. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of Clodronate decreases the frequency of skeletal metastases in bisphosphonates and new insights into their mechanisms of women with breast cancer. Bone 1996; 19: 663–7. action. J Bone Miner Res 1999; 14(Suppl. 2): 53–65. 7. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I for the 25. Adami S, Zamberlan N. Adverse effects of bisphosphonates: Finnish Leukaemia Group. Randomised placebo controlled A comparative review. Drug Safety 1996; 14: 158–70. multicentre trial of clodronate in multiple myeloma. Lancet 26. Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marco- 1992; 340: 1049–52. longo R. Effects of 4-year treatment with once-weekly clodro- 8. Paterson A, Powles T, Kanis J, McCloskey E, Hanson J, Ashley S. nate on prevention of corticosteroid-induced bone loss and Double-blind controlled trial of oral clodronate in patients with fractures in patients with arthritis: evaluation with dual-energy bone metastases from breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Age and Ageing Oxford University Press

Tailored group exercise (Falls Management Exercise — FaME) reduces falls in community-dwelling older frequent fallers (an RCT)

Loading next page...
 
/lp/oxford-university-press/tailored-group-exercise-falls-management-exercise-fame-reduces-falls-XRvsDNGQJ5

References (12)

Publisher
Oxford University Press
Copyright
© The Author 2005. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
ISSN
0002-0729
eISSN
1468-2834
DOI
10.1093/ageing/afi174
pmid
16267192
Publisher site
See Article on Publisher Site

Abstract

Research letters 5. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in bone metabolism in rats with adjuvant arthritis. Inflammation cancer patients. Cancer Treat Rev 1996; 22: 265–87. 2004; 28: 15–21. 6. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. 24. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of Clodronate decreases the frequency of skeletal metastases in bisphosphonates and new insights into their mechanisms of women with breast cancer. Bone 1996; 19: 663–7. action. J Bone Miner Res 1999; 14(Suppl. 2): 53–65. 7. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I for the 25. Adami S, Zamberlan N. Adverse effects of bisphosphonates: Finnish Leukaemia Group. Randomised placebo controlled A comparative review. Drug Safety 1996; 14: 158–70. multicentre trial of clodronate in multiple myeloma. Lancet 26. Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marco- 1992; 340: 1049–52. longo R. Effects of 4-year treatment with once-weekly clodro- 8. Paterson A, Powles T, Kanis J, McCloskey E, Hanson J, Ashley S. nate on prevention of corticosteroid-induced bone loss and Double-blind controlled trial of oral clodronate in patients with fractures in patients with arthritis: evaluation with dual-energy bone metastases from breast cancer.

Journal

Age and AgeingOxford University Press

Published: Nov 1, 2005

There are no references for this article.